Effects of renal sympathetic denervation and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy

详细信息    查看全文

• 作者：X. Ding ; X. Xu ; Y. Yan ; X. Song ; S. Liu ; G. Wang ; D. Su ; Q. Jing ; Y. Qin
• 关键词：Renal sympathetic denervation ; Angiotensin ; converting enzyme inhibitor ; Myocardial hypertrophy ; Spontaneously hypertensive rats ; Rats ; inbred strain ; Renale Sympathikusdenervation ; Angiotensin ; converting ; Enzym ; Inhibitor ; Myokardhypertrophie ; Spontan hypertensive Ratten ; Ratten ; Inzuchtstamm
• 刊名：Herz
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：40
• 期：4
• 页码：695-701
• 全文大小：832 KB
• 参考文献：1.Diamond JA, Phillips RA (2005) Hypertensive heart disease. Hypertens Res 28:191-02PubMed View Article
  2.Agabiti-Rosei E, Muiesan ML (2002) Left ventricular hypertrophy and heart failure in women. J Hypertens Suppl 20:S34–S38PubMed
  3.Ruilope LM, Schmieder RE (2008) Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 21:500-08PubMed View Article
  4.Lindholm LH, Carlberg B, Samuelsson O (2005) Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545-553PubMed View Article
  5.Williams B, Lacy PS, Thom SM et al (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113:1213-225PubMed View Article
  6.Yang CM, Kandaswamy V, Young D, Sen S (1997) Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc Res 36:236-45PubMed View Article
  7.Brilla CG, Janicki JS, Weber KT (1991) Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 69:107-15PubMed View Article
  8.Brooks WW, Bing OH, Robinson KG et al (1997) Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 96:4002-010PubMed View Article
  9.Brilla CG, Pick R, Tan LB et al (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67:1355-364PubMed View Article
  10.Brilla CG, Matsubara LS, Weber KT (1993) Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71:12A-6APubMed View Article
  11.Mancia G, Grassi G, Giannattasio C, Seravalle G (1999) Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34:724-28PubMed View Article
  12.Pimenta E, Oparil S (2012) Renal sympathetic denervation for treatment of hypertension. Curr Treat Options Cardiovasc Med in press
  13.Brandt MC, Mahfoud F, Reda S et al (2012) Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 59:901-09PubMed View Article
  14.Bombelli M, Facchetti R, Carugo S et al (2009) Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 27:2458-464PubMed View Article
  15.Franklin SS, Wachtell K, Papademetriou V et al (2005) Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a life substudy. Hypertension 46:492-99PubMed View Article
  16.Asai K, Yang GP, Geng YJ et al (1999) Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G (salpha) mouse. J Clin Invest 104:551-58PubMed Central PubMed View Article
  17.Krum H, Schlaich M, Whitbourn R et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275-281PubMed View Article
  18.Perlini S, Palladini G, Ferrero I et al (2005) Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 46:1213-218PubMed View Article
  19.Levick SP, Murray DB, Janicki JS, Brower GL (2010) Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension 55:270-76PubMed Central PubMed View Article
  20.Schlaich MP, Sobotka PA, Krum H et al (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361:932-34PubMed View Article
  21.DiBona GF (2004) The sympathetic nervous system and hypertension: recent developments. Hypertension 43:147-50PubMed View Article
  22.Wyss JM, Oparil S, Sripairojthikoon W (1992) Neuronal control of the kidney: contribution to hypertension. Can J Physiol Pharmacol 70:759-70PubMed View Article
  23.Brilla CG, Zhou G, Matsubara L, Weber KT (1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26:809-20PubMed View Article
  24.Villarreal FJ, Kim NN, Ungab GD et al (1993) Identification of functional angiotensin ii receptors on rat cardiac fibroblasts. Circulation 88:2849-861PubMed View Article
  25.Chevalier B, Heudes D, Heymes C et al (1995) Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR. Circulation 92:1947-953PubMed View Article
  26.Dias LD, Casali KR, Leguisamo NM et al (2011) Renal denervation in an animal model of diabetes and hypertension: impact on the autonomic nervous
• 作者单位：X. Ding (1) (2)
  X. Xu (1)
  Y. Yan (3)
  X. Song (1)
  S. Liu (1)
  G. Wang (4)
  D. Su (5)
  Q. Jing (1) (4)
  Y. Qin (1)
  
  1. Department of Cardiology, Changhai Hospital, 2nd Military Medical University, 168 Changhai Road, 200433, Shanghai, PR China
  2. Cardiovascular Therapeutic Centre, The 117 Hospital of the Chinese People’s Liberation Army, Hangzhou, Zhejiang, PR China
  3. Department of Cardiothoracic Surgery, Changhai Hospital, Second Military Medical University, Shanghai, PR China
  4. Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao-Tong University School of Medicine, Shanghai, PR China
  5. School of Pharmacy, Second Military Medical University of China, Shanghai, PR China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  
• 出版者：Urban & Vogel
• ISSN：1615-6692

文摘

Objectives The aim of this study was to investigate whether renal sympathetic denervation (RSD) is more effective on myocardial hypertrophy than the angiotensin-converting enzyme inhibitor (ACEI) perindopril in spontaneously hypertensive rats (SHRs). Methods After bilateral renal denervation blood pressure (BP) was measured every 10?days. On day 50 the heart was (histo)pathologically examined. The ventricular weight to body weight ratios (VW/BW), myocardial diameter and collagen volume fraction (CVF) were calculated, and cardiac hypertrophy marker genes were analyzed by RT-PCR. Results At the baseline evaluation all groups had comparable BP. After treatment the BP of the RSD group was significantly reduced (p-lt;-.05). The BP of the RSD group was lower than that of the perindopril group on days 10, 20 and 30th (p-lt;-.05) but on day 50 systolic BP of the RSD group was significantly higher (p-lt;-.05) whereas there were no significant differences in diastolic BP. The VW/BW decreased in the RSD group, whereas the value did not change significantly in the perindopril group. The myocardial diameter of the left ventricular cardiomyocytes was also significantly lower in the RSD group and stayed the same in the perindopril group. Collagen volume fraction (CVF) in the RSD group was significantly lower than in the perindopril group (p-lt;-.05). Significant changes in the expression levels of NPPA, MYH7, and MYH6 (P-lt;-.05) were observed in the RD-SHR groups (p-lt;-.05). There was a significant difference in the expression level of MYH6 (p-lt;-.05) between the RSD group and the perindopril group but the expression levels of NPPA and MYH7 were not significantly different. Conclusion In this study, RSD had a significant antihypertensive effect and inhibited hypertensive-induced cardiac hypertrophy in SHRs and showed advantages compared with ACEI in decreasing BP in the early stage and in inhibiting myocardial fibrosis.